Givlaari (Givosiran Sodium) Patent Expiration, LOE Window & CMS Spending
Givlaari (Givosiran Sodium) by Alnylam Pharmaceuticals: FDA Orange Book core substance LOE 2034-10-03, 0 AB generics, $39.9M 2024 CMS Part D & Medicaid spend.
| Regulatory & Reimbursement Dimension | Verified Value |
|---|---|
| Consolidated Sponsor | Alnylam Pharmaceuticals |
| FDA Application & Pathway | N212194 (NDA) |
| Exclusivity / Cliff Horizon | Mid-Term Protection (2031-2035) |
| Core Active-Ingredient LOE Date | 2034-10-03 |
| Last Listed Patent or Exclusivity Date | 2034-10-03 |
| Orange Book Patents (*PED Extensions) | 8 patents (0 *PED) |
| Active AB-Rated Generic Competitors | 0 |
| 2024 CMS Total Public Spend | $39.9M |
| 2024 Medicare Part D Spend | $20.9M |
| 2024 Medicaid Spend | $18.9M |
| Reported Wholesale Price Change (CA SB 17) | 0 statutory filings in 2023 to 2026 panel |
Related Filings Across Meru Platforms
Verified cross-ledger federal filings for Alnylam Pharmaceuticals across sibling Meru public-data platforms.